CME

CME

By ReachMDMedicine
Download on the App Store

CME episodes

  • The Future of Immunoprophylaxis and RSV Vaccines
    Host: Vikram Anand, MD, PhD
    Guest: Priya Soni, MD, FAAP

    This program discusses respiratory syncytial virus (RSV), a ubiquitous infection capable of infecting all age groups with a high probability of reinfection. However, the clinical presentation of the disease across age groups is non-specific, and clinicians often fail to identify individuals within the population at the highest risk for poor outcomes. RSV vaccination attempts have historically been unsuccessful. Multiple potential vaccines are proceeding to the late stage of development; however, there is little awareness of these potential options. This program addresses these topics, as well as vaccine hesitancy, as it is often a barrier to improving vaccination compliance, as it exists both at the provider and patient level.

    5 min
  • Cardio-Oncology: Key Clinical Data from ACC.23
    Guest: Ana Barac, MD, PhD

    The American College of Cardiology's 72nd Scientific Session & Expo featured the latest advancements in all fields of cardiovascular medicine, including cardio-oncology. To learn more, Dr. Javed Butler sits down with Dr. Ana Barac from the MedStar Washington Hospital Center to take a look at clinical data from the STOP-CA trial.

    4 min
  • Expert Answers to Common Questions About MET Exon 14–Skipping Mutations in NSCLC
    Host: Mark Socinski, MD
    Guest: Patrick Forde, M.B.B.Ch.
    Guest: Karen Reckamp, MS, MD

    Non-small cell lung cancer (NSCLC) is a highly heterogeneous disease, and research has evolved its diagnosis and treatment through the discovery of genetic alterations and molecular pathways, personalizing treatment based on tumor mutation(s). The molecular characterization of tumors using techniques such as next-generation sequencing (NGS) has expanded the understanding of actionable molecular alterations, and in tandem has accelerated the development of drugs to inhibit alterations with greater specificity, leading to the development of novel target-selected agents in NSCLC.

    The NCCN Guidelines strongly advise assessment of at least 8 targets for NSCLC by NGS, including MET exon 14–skipping mutations (METex14). The FDA has approved two MET inhibitors, capmatinib and tepotinib, for patients with METex14 metastatic NSCLC, and there is ongoing research for other targeted agents. Studies have established that treatment with MET-targeted therapies improves outcomes in patients with METex14, as opposed to patients receiving chemotherapy and/or immunotherapy, which generate a modest activity response.

    AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment and management of patients with cancer to verify where clinical practice gaps exist. That’s why this activity will …

    16 min
  • Prognostic Tools in the Management of ADPKD
    Host: Meyeon Park, MD, MAS
    Host: Anjay Rastogi, MD, PhD

    This Expert Exchange webcast is designed to help improve clinicians’ ability to utilize prognostic tools to monitor disease progression and implement appropriate treatment strategies in patients with ADPKD.

    This activity is not available for continuing education credit.

    24 min
  • Optimizing Medical Management of Uterine Fibroids: Achieving Patient-Centered Goals and Outcomes
    Host: Andrew M. Kaunitz, MD, FACOG

    By the age of 50, ultrasound imaging demonstrates that 70%-80% of women have fibroids. Uterine fibroids are associated with disability similar to other chronic diseases. They can even lead to lower vitality and social function than are experienced by women with breast cancer. Fibroid-related hysterectomies account for 45% of all US hysterectomies, but a surgical approach is no longer one size fits many. Join Dr. Andrew Kaunitz as he describes the clinical presentations of fibroids and how newly emergent medical options greatly improve fibroid-related symptoms, provide time to consider other alternatives, and can be used to bridge the transition to menopause.

    0 min
  • Alloimmune Thrombocytopenia in the Fetus and Newborn
    Host: Lee P. Shulman, MD, FACMG, FACOG
    Guest: James B. Bussel, MD

    This program is no longer available for credit.

    Program Chairman:
    Roberto Romero, MD, DMedSci
    Chief, Perinatology Research Branch
    Division of Maternal-Fetal Medicine and Obstetrics
    Division of Intramural Research
    NICHD/NIH/DHHS
    Editor-in-Chief for Obstetrics
    The American Journal of Obstetrics and Gynecology

    As the platelet equivalent of hemolytic disease of the fetus and newborn, fetal and neonatal alloimmune thrombocytopenia (FNAIT) is an uncommon yet complex and life-threatening bleeding disorder that results from incompatibility between mother and baby for platelet-specific antigens. Despite relatively normal platelet function, in the setting of severe thrombocytopenia, intracranial hemorrhage is a consequence. Drs. Shulman and Bussel discuss advances in management strategies and concrete steps you can take to lower the risk and stop the progression of this disorder in your patients.

    19 min
  • Targeting the Fc Receptor Pathway to Treat Red Blood Cell Alloimmunization
    Host: Lee P. Shulman, MD, FACMG, FACOG
    Guest: Kenneth J. Moise Jr., MD

    This program is no longer available for credit.

    Program Chairman:
    Roberto Romero, MD, DMedSci
    Chief, Perinatology Research Branch
    Division of Maternal-Fetal Medicine and Obstetrics
    Division of Intramural Research
    NICHD/NIH/DHHS
    Editor-in-Chief for Obstetrics
    The American Journal of Obstetrics and Gynecology

    How well do you understand the biology of hemolytic disease of the fetus and newborn (HDFN)? What about its connection to the FcRn receptor pathway and IgG? Drs. Lee Shulman and Ken Moise go beyond the basics taught in medical school immunology and look more closely at FcRn’s role in protecting IgG. With an improved understanding of these mechanisms, we can expand therapeutic targets beyond the fetus and newborn and finally put the needles away.

    13 min
  • Imaging in the Diagnosis and Management of ADPKD
    Host: Theodora A. Potretzke, MD
    Guest: Fouad T. Chebib, MD

    This Expert Exchange webcast is designed to help improve clinicians’ understanding of the role radiologic imaging plays in the diagnosis and management of ADPKD.

    This activity is not available for continuing education credit.

    28 min